JP2008522981A5 - - Google Patents

Download PDF

Info

Publication number
JP2008522981A5
JP2008522981A5 JP2007544636A JP2007544636A JP2008522981A5 JP 2008522981 A5 JP2008522981 A5 JP 2008522981A5 JP 2007544636 A JP2007544636 A JP 2007544636A JP 2007544636 A JP2007544636 A JP 2007544636A JP 2008522981 A5 JP2008522981 A5 JP 2008522981A5
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutical composition
hydrogen
aryl
aralkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007544636A
Other languages
English (en)
Japanese (ja)
Other versions
JP4990155B2 (ja
JP2008522981A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/044451 external-priority patent/WO2006063154A1/en
Publication of JP2008522981A publication Critical patent/JP2008522981A/ja
Publication of JP2008522981A5 publication Critical patent/JP2008522981A5/ja
Application granted granted Critical
Publication of JP4990155B2 publication Critical patent/JP4990155B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2007544636A 2004-12-07 2005-12-07 プロテアソームを阻害するための組成物 Expired - Lifetime JP4990155B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US63436604P 2004-12-07 2004-12-07
US60/634,366 2004-12-07
US65593005P 2005-02-23 2005-02-23
US60/655,930 2005-02-23
PCT/US2005/044451 WO2006063154A1 (en) 2004-12-07 2005-12-07 Composition for proteasome inhibition

Publications (3)

Publication Number Publication Date
JP2008522981A JP2008522981A (ja) 2008-07-03
JP2008522981A5 true JP2008522981A5 (enExample) 2008-10-02
JP4990155B2 JP4990155B2 (ja) 2012-08-01

Family

ID=36143200

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007544636A Expired - Lifetime JP4990155B2 (ja) 2004-12-07 2005-12-07 プロテアソームを阻害するための組成物

Country Status (17)

Country Link
US (1) US7737112B2 (enExample)
EP (3) EP2261236B1 (enExample)
JP (1) JP4990155B2 (enExample)
KR (1) KR101299821B1 (enExample)
CN (2) CN102847136A (enExample)
AT (1) ATE499109T1 (enExample)
AU (1) AU2005313975B2 (enExample)
CA (1) CA2589921C (enExample)
CY (1) CY1111489T1 (enExample)
DE (1) DE602005026556D1 (enExample)
DK (1) DK1819353T3 (enExample)
ES (2) ES2408216T3 (enExample)
HU (1) HUE027850T2 (enExample)
IL (1) IL183607A (enExample)
PL (3) PL1819353T3 (enExample)
PT (3) PT2260835E (enExample)
WO (1) WO2006063154A1 (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE494298T1 (de) 2004-04-15 2011-01-15 Proteolix Inc Verbindungen zur proteasomenzymhemmung
US8198270B2 (en) * 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
SI2030981T1 (sl) * 2004-05-10 2014-11-28 Onyx Therapeutics, Inc. Spojine za inhibiranje proteasomskega encima
US9034846B2 (en) * 2004-10-10 2015-05-19 Universite De Liege Use of cyclodextrin for treatment and prevention of bronchial inflammatory diseases
EP2623113B1 (en) 2005-11-09 2017-05-31 Onyx Therapeutics, Inc. Compound for enzyme inhibition
NZ597545A (en) 2006-06-19 2013-07-26 Proteolix Inc Peptide epoxyketones for proteasome inhibition
CA2701778C (en) 2007-10-04 2018-09-11 Onyx Therapeutics, Inc. Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
WO2010039762A2 (en) * 2008-10-01 2010-04-08 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions comprising boronic acid compounds
JP5675629B2 (ja) * 2008-10-21 2015-02-25 オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. ペプチドエポキシケトンを用いた併用療法
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
EP2238973A1 (en) 2009-04-07 2010-10-13 Cephalon France Lyophilized preparations of proteasome inhibitors
US11020363B2 (en) 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
KR101522918B1 (ko) 2009-05-29 2015-05-27 사이덱스 파마슈티칼스, 인크. 사이클로덱스트린 유도체를 포함하는 주사용 멜팔란 조성물 및 이의 제조 및 사용 방법
WO2011060179A1 (en) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
AU2011223795B2 (en) 2010-03-01 2015-11-05 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
CA2795559A1 (en) 2010-04-07 2011-11-03 Onyx Therapeutics, Inc. Crystalline peptide epoxyketone immunoproteasome inhibitor
SG10201606063RA (en) 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
HUE058834T2 (hu) 2012-02-15 2022-09-28 Cydex Pharmaceuticals Inc Elõállítási eljárás ciklodextrin-származékokhoz
MX353603B (es) 2012-02-28 2018-01-19 Cydex Pharmaceuticals Inc Composiciones de ciclodextrina alquilada y procesos para preparar y utilizar las mismas.
EP2827861A4 (en) * 2012-03-19 2016-03-16 Aposignal Bioscience Llc COMPOSITION AND METHODS FOR CELLULAR MODULATION
AU2013259573B2 (en) 2012-05-08 2018-02-15 Onyx Therapeutics, Inc. Cyclodextrin complexation Methods for Formulating Peptide Proteasome Inhibitors
MY165002A (en) * 2012-05-08 2018-02-28 Onyx Therapeutics Inc Cylodextrin complexation methods for formulating peptide proteasome inhibitors
WO2014011695A2 (en) 2012-07-09 2014-01-16 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
WO2014015027A1 (en) * 2012-07-18 2014-01-23 Onyx Therapeutics, Inc. Liposomal compositions of epoxyketone-based proteasome inhibitors
WO2014018807A1 (en) * 2012-07-26 2014-01-30 Centrax International, Inc. Peptide epoxyketone compounds
CN109180780B (zh) * 2012-07-26 2022-03-18 圣特莱国际公司 多肽环氧酮化合物
CA2881999A1 (en) * 2012-08-14 2014-02-20 Abdelmalik Slassi Fluorinated epoxyketone-based compounds and uses thereof as proteasome inhibitors
US9636376B2 (en) 2012-09-11 2017-05-02 Innopharma, Inc. Stable compositions of peptide epoxy ketones
WO2014066274A1 (en) 2012-10-22 2014-05-01 Cydex Pharmaceuticals, Inc. Alkylated cyclodextrin compositions and processes for preparing and using the same
PE20151024A1 (es) * 2012-11-30 2015-07-27 Glaxosmithkline Llc Composicion farmaceutica novedosa
US10076384B2 (en) 2013-03-08 2018-09-18 Symple Surgical, Inc. Balloon catheter apparatus with microwave emitter
SG10201913777XA (en) 2013-03-13 2020-03-30 Sanofi Sa Compositions comprising anti-cd38 antibodies and carfilzomib
SG11201507106PA (en) 2013-03-14 2015-10-29 Onyx Therapeutics Inc Dipeptide and tripeptide epoxy ketone protease inhibitors
AR095426A1 (es) 2013-03-14 2015-10-14 Onyx Therapeutics Inc Inhibidores tripeptídicos de la epoxicetona proteasa
AU2014290012B2 (en) 2013-07-19 2020-01-16 Onyx Therapeutics, Inc. Peptide epoxyketone proteasome inhibitors in combination with PIM kinase inhibitors for treatment of cancers
WO2016011088A2 (en) * 2014-07-14 2016-01-21 Centrax International, Inc. Epoxyketone compounds for enzyme inhibition
HUE063851T2 (hu) 2014-08-22 2024-02-28 Cydex Pharmaceuticals Inc Frakcionált alkilezett ciklodextrin készítmények és eljárás ezek elõállítására és alkalmazására
WO2016170489A1 (en) 2015-04-24 2016-10-27 Fresenius Kabi Oncology Ltd. Pharmaceutical compositions of proteasome inhibitor
JP7085994B2 (ja) * 2015-11-17 2022-06-17 博蔚醫藥生物科技股▲ふん▼有限公司 線維症疾患の治療及び/又は予防用アミノナフトキノン化合物
TWI759301B (zh) * 2016-05-24 2022-04-01 美商安美基公司 聚乙二醇化卡非佐米化合物
UA125648C2 (uk) 2016-08-05 2022-05-11 Емджен Інк. Синтез (s)-2-аміно-4-метил-1-((r)-2-метилоксиран-2-іл)-пентан-1-ону та його фармацевтично прийнятних солей
WO2018038687A1 (en) 2016-08-22 2018-03-01 Mustafa Nevzat Ilaç Sanayii A.Ş. Pharmaceutical formulations comprising a bortezomib-cyclodextrin complex
US10098890B2 (en) 2016-10-29 2018-10-16 Cipla Limited Stable carfilzomib formulations
WO2018138557A1 (en) 2017-01-24 2018-08-02 Orbicular Pharmaceutical Technologies Pvt. Ltd. Ready-to-use carfilzomib compositions
BR112020005079A2 (pt) 2017-09-14 2020-09-15 Glaxosmithkline Intellectual Property Development Limited tratamento de combinação para câncer
WO2019099715A1 (en) 2017-11-16 2019-05-23 Amgen Inc. Stable compositions of pegylated carfilzomib compounds
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
CN115038723A (zh) 2019-11-18 2022-09-09 锡德克斯药物公司 烷基化环糊精组合物及其制备和使用方法
US12698348B2 (en) 2020-09-24 2026-08-04 Cydex Pharmaceuticals, Inc. Alkylated cyclodextrin compositions and processes for preparing and using the same
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
US20250295771A1 (en) 2022-05-11 2025-09-25 Celgene Corporation Methods and uses related to t cell therapy and production of same
US20260166082A1 (en) 2022-11-02 2026-06-18 Celgene Corporation Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
AU2024321532A1 (en) 2023-08-09 2026-01-29 Amgen Inc. Diluted carfilzomib for use in treating multiple myeloma
EP4782438A1 (en) * 2023-10-30 2026-07-29 Shanghai Huilun Pharmaceutical Co., Ltd. Epoxy compound and use thereof
EP4685151A1 (en) 2024-07-24 2026-01-28 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Proteasome inhibitor

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5135919A (en) * 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
US5441944A (en) * 1989-04-23 1995-08-15 The Trustees Of The University Of Pennsylvania Substituted cyclodextrin sulfates and their uses as growth modulating agents
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5340736A (en) 1991-05-13 1994-08-23 The President & Fellows Of Harvard College ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting
WO1998010779A1 (en) 1996-09-13 1998-03-19 New York University Method for treating parasitic diseases with proteasome inhibitors
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6046177A (en) 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
ES2210769T3 (es) 1997-06-13 2004-07-01 Cydex Inc. Compuesto con vida de almacenamiento prolongada que comprende ciclodextrina y medicamentos y promedicamentos que se descomponen en componentes insolubles en agua.
US6831099B1 (en) 1999-05-12 2004-12-14 Yale University Enzyme inhibition
JP2003528039A (ja) * 1999-10-20 2003-09-24 オステオスクリーン,インコーポレイテッド 骨および毛成長を刺激するためのプロテアソーム活性のインヒビター
EP1463719A2 (en) * 2002-01-08 2004-10-06 Eisai Co., Ltd Eponemycin and epoxomicin analogs and uses thereof
AU2003220685A1 (en) * 2002-04-09 2003-10-27 Greenville Hospital System Metastasis modulating activity of highly sulfated oligosaccharides
ATE494298T1 (de) 2004-04-15 2011-01-15 Proteolix Inc Verbindungen zur proteasomenzymhemmung
US7232818B2 (en) * 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
SI2030981T1 (sl) * 2004-05-10 2014-11-28 Onyx Therapeutics, Inc. Spojine za inhibiranje proteasomskega encima

Similar Documents

Publication Publication Date Title
JP2008509166A5 (enExample)
RU2397168C2 (ru) Производные тиофена в качестве ингибиторов снк 1
IL276322B2 (en) Lipid-like nanocomplexes and uses thereof
ES2549763T3 (es) Composición para inhibición del proteasoma
CY1121782T1 (el) Διαδικασια για ξηρανση της bibw2992, tων αλατων αυτης και στερεων φαρμακευτικων σκευασματων που περιλαμβανουν αυτο το δραστικο συστατικο
UY28132A1 (es) Derivados de pirrolopirimidina
NO20090328L (no) Nye forbindelser 385
TN2010000026A1 (fr) Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
NO20072515L (no) 2-amido-4-fenyltnazolderivater, fremstilling og terapeutsik anvendelse derav
JP2006509749A5 (enExample)
NO20085060L (no) Triazolpyrazinderivater anvendelige som anti-cancermidler
MX2012001953A (es) Composiciones fotosensibilizantes.
CY1114803T1 (el) Παραγωγα πυριμιδινο σουλφοναμιδιου ως ρυθμιστες υποδοχεων χημειοκινης
RU2016135952A (ru) Композиции ингибитора дофа-декарбоксилазы
BR112013012057A2 (pt) compostos de lipoil e seu uso para o tratamento de lesões isquêmicas
JP2003306481A5 (enExample)
MEP42908A (en) Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use of the same as medicaments, and medicament containing such compounds
RU2002100058A (ru) Кристаллические производные 1-метилкарбапенема
AR054129A1 (es) Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7
NO20075637L (no) 4-fenyl-5-okso-1,4,5,6,7,8-heksahydrokinolinderivater som medikamenter for behandling av infertilitet
BRPI0609783A8 (pt) composto, utilização do mesmo, composição farmacêutica ou cosmética, e, utilização cosmética de um composto
CL2020001156A1 (es) Formulaciones de liberación prolongada para aplicaciones intra-articulares.
EA201070626A1 (ru) Система доставки лекарственного средства для введения водорастворимого катионного и амфифильного фармацевтически активного вещества
BRPI0408270A (pt) composição farmacêutica compreendendo ácido 5-metil-2-(2'cloro-6'-fluoroanilino)fenilacético
FR2869615B1 (fr) Derives de l'acide butanoique, procedes pour leur preparation, compositions pharmaceutiques les contenant et leurs applications therapeutiques